Bayer
Digital Pharma: Bayer tweets breach ABPI Code of Practice
July 5, 2011Medical Communications Bayer, Code of Practice, Digital Pharma blog, PMCPA, Twitter, medical communications news, social media
Bayer’s use of Twitter has caused the first social media breach of the ABPI Code of Practice. Code regulator the …
Xarelto receives FDA approval
July 4, 2011Sales and Marketing Bayer, Eliquis, Johnson & Johnson, Pradaxa, Xarelto, anticoagulant
Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep …
Bayer submits Lucentis rival for European approval
June 7, 2011Sales and Marketing Bayer, Lucentis, Regeneron, VEGF Trap-Eye
Bayer Healthcare has submitted its new eye drug to European regulators for approval to treat age-related macular degeneration (wet AMD). …
Bayer wields the axe at Emeryville plant
May 31, 2011Manufacturing and Production Bayer, Emeryville, MS
Bayer Healthcare says it will cut 540 jobs at a production facility in Emeryville, California, next year after shifting production …
Bayer contraceptive advert breaches Code of Practice
May 27, 2011Medical Communications ABPI Code of Practice, Bayer, Multaq, Sanofi, Yasmin
Bayer Healthcare has been singled out for “particular censure” by the PMCPA, the body which regulates the ABPI Code of …
FDA fast-tracks Bayer’s GIST drug regorafenib
May 10, 2011Sales and Marketing Bayer, GIST, regorafenib
The assessment of Bayer HealthCare’s investigational drug regorafenib is to be fast-tracked by US authorities for the treatment of stomach …
Digital Pharma: Bayer UK’s Twitter slip-up
April 26, 2011Medical Communications ABPI Code of Practice, Bayer, Digital Pharma blog, PMCPA, Twitter, medicial communications
There seems to be some confusion at Bayer UK over what communications can be sent over Twitter. The company is …
Bayer defends Yasmin against BMJ studies
April 26, 2011Sales and Marketing Bayer, Yasmin, contraception
Bayer has rallied strongly behind its top-selling contraceptive brand Yasmin after two studies in the British Medical Journal questioned the …
Bayer drug enters phase III for diabetic macular oedema
April 11, 2011Sales and Marketing Bayer, Lucentis, ophthalmology
Bayer and partner Regeneron have begun late stage trials for their VEGF Trap Eye candidate for diabetic macular oedema. The …
Bayer-helmed oncology biomarker project launched
March 14, 2011Manufacturing and Production, Research and Development AstraZeneca, Bayer, Janssen, Max Planck Institute, Merck, OncoTrack, Pfizer, Roche, biomarkers, oncology
A project to develop the next generation of oncology biomarkers has been launched in Berlin. The pharma industry and European …
Bayer goes for pharma growth
March 1, 2011Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto
While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …
Bayer’s regorafenib gains orphan status for GIST
February 4, 2011Research and Development, Sales and Marketing Bayer, FDA, GIST, gastrointestinal stromal tumours, orphan drug, regorafenib
Bayer’s investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumours (GIST) …
Bayer and Zydus Cadila sign India deal
February 4, 2011Sales and Marketing Bayer, India, Indian pharmaceutical industry, Zydus Cadila
Bayer HealthCare and the Indian company Zydus Cadila have signed a deal to form a new joint venture. A new …
Digital Pharma: NHS thrombosis e-learning
January 14, 2011Medical Communications Bayer, Boehringer Ingelheim, Digital Pharma blog, NHS training, Pfizer, Sanofi-Aventis, VTE, e-learning, venous thromboembolism
The NHS has launched a best-practice website to help educate healthcare professionals about one of the most common causes of …
Bayer submits new Xarelto indications for European approval
January 6, 2011Sales and Marketing Bayer, DVT, Xarelto, atrial fibrillation, deep vein thrombosis, pulmonary embolism, rivaroxaban, stroke prevention
Bayer is seeking European regulatory approval for a batch of new indications for its oral anticoagulant Xarelto. The company is …
Latest content
